Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models

Elements of the hypoxia inducible factor (HIF) transcriptional system, a key regulator of the cellular hypoxic response, are up-regulated in a range of cancer cells. HIF is fundamentally involved in tumor angiogenesis, invasion, and energy metabolism. Inhibition of the transcriptional activity of HIF may be of therapeutic benefit to cancer patients. We recently described the identification of two marine pyrroloiminoquinone alkaloids with potent activity in inhibiting the interaction between the oncogenic transcription factor HIF-1α and the coactivator protein p300. Herein, we present further characterization data for these two screening hits: discorhabdin H (1) and discorhabdin L (2), with a specific focus on their anti-angiogenic and anti-tumor effects. We demonstrated that only discorhabdin L (2) possesses excellent anti-angiogenic activity in inhibiting endothelial cell proliferation and tube formation, as well as decreasing microvessel outgrowth in the ex vivo rat aortic ring assay. We further showed that discorhabdin L (2) significantly inhibits in vivo prostate tumor growth in a LNCaP xenograft model. In conclusion, our findings suggest that discorhabdin L (2) represents a promising HIF-1α inhibitor worthy of further drug development.

[1]  Chris P. Ponting,et al.  Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases* , 2016, The Journal of Biological Chemistry.

[2]  Kristina M. Cook,et al.  Screening and Biological Effects of Marine Pyrroloiminoquinone Alkaloids: Potential Inhibitors of the HIF-1α/p300 Interaction. , 2016, Journal of natural products.

[3]  Kristina M. Cook,et al.  Structural Elucidation and Synthesis of Eudistidine A: An Unusual Polycyclic Marine Alkaloid that Blocks Interaction of the Protein Binding Domains of p300 and HIF-1α. , 2015, Journal of the American Chemical Society.

[4]  D. Venzon,et al.  Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer , 2014, Molecular Cancer.

[5]  Shi-Biao Wu,et al.  Discorhabdins and pyrroloiminoquinone-related alkaloids. , 2011, Chemical reviews.

[6]  Y. Kita,et al.  Synthesis of the Marine Pyrroloiminoquinone Alkaloids, Discorhabdins , 2010, Marine drugs.

[7]  Kristina M. Cook,et al.  Epidithiodiketopiperazines Block the Interaction between Hypoxia-inducible Factor-1α (HIF-1α) and p300 by a Zinc Ejection Mechanism* , 2009, The Journal of Biological Chemistry.

[8]  Neil Vargesson,et al.  Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation , 2009, Proceedings of the National Academy of Sciences.

[9]  D. Livingston,et al.  Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. , 2004, Cancer cell.

[10]  K. M. Marshall,et al.  Cytotoxic pyrroloiminoquinones from four new species of South African latrunculid sponges. , 2004, Journal of natural products.

[11]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[12]  H. Dyson,et al.  Structural basis for Hif-1α/CBP recognition in the cellular hypoxic response , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  D. Livingston,et al.  Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1α , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Peet,et al.  Asparagine Hydroxylation of the HIF Transactivation Domain: A Hypoxic Switch , 2002, Science.

[15]  S. Libutti,et al.  Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay. , 2000, Biochemical and biophysical research communications.